Arcutis Biotherapeutics (ARQT) Cash from Operations Growth (1y) (2020 - 2026)
Arcutis Biotherapeutics (ARQT) Cash from Operations Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 75.58% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -119.28% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 100.14% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 151.70% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 56.79% |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 3,800.93% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,800.93% |
| Mar 31, 2026 | 107.37% |
| Dec 31, 2025 | 3,600.67% |
| Sep 30, 2025 | 94.94% |
| Jun 30, 2025 | 100.72% |
| Mar 31, 2025 | 3.87% |
| Dec 31, 2024 | 98.67% |
| Sep 30, 2024 | 21.13% |
| Jun 30, 2024 | 32.14% |
| Mar 31, 2024 | 60.67% |
| Dec 31, 2023 | 20.86% |
| Sep 30, 2023 | 35.03% |
| Jun 30, 2023 | -7.27% |
| Mar 31, 2023 | -41.02% |
| Dec 31, 2022 | -37.43% |
| Sep 30, 2022 | -65.58% |
| Jun 30, 2022 | -72.98% |
| Mar 31, 2022 | -23.31% |
| Dec 31, 2021 | -58.76% |
| Sep 30, 2021 | -21.35% |